title: Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.
abstract: Purpose. WB-MRI is mainly used for tumor detection and surveillance. The purpose of this study is to establish the feasibility of WB-MRI at 3T for lesion characterization, with DWI/ADC-mapping and contrast-enhanced sequences, in patients with neurofibromatosis type 2 (NF-2) and schwannomatosis. Materials and Methods. At 3T, WB-MRI was performed in 11 subjects (10 NF-2 and 1 schwannomatosis) with STIR, T1, contrast-enhanced T1, and DWI/ADC mapping (b = 50, 400, 800 s/mm(2)). Two readers reviewed imaging for the presence and character of peripheral lesions. Lesion size and features (signal intensity, heterogeneity, enhancement characteristics, and ADC values) were recorded. Descriptive statistics were reported. Results. Twenty-three lesions were identified, with average size of 4.6 ± 2.8 cm. Lesions were characterized as tumors (21/23) or cysts (2/23) by contrast-enhancement properties (enhancement in tumors, no enhancement in cysts). On T1, tumors were homogeneously isointense (5/21) or hypointense (16/21); on STIR, tumors were hyperintense and homogeneous (10/21) or heterogeneous (11/21); on postcontrast T1, tumors enhanced homogeneously (14/21) or heterogeneously (7/21); on DWI, tumor ADC values were variable (range 0.8-2.7), suggesting variability in intrinsic tumor properties. Conclusion. WB-MRI with quantitative DWI and contrast-enhanced sequences at 3T is feasible and advances the utility of WB-MRI not only to include detection, but also to provide additional metrics for lesion characterization.
authors: The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ; Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors: Laura M
authors: LM
authors: Fayad
authors: Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ; The Johns Hopkins Hospital Comprehensive Neurofibromatosis Center, Department of Neurology, The Johns Hopkins Hospital, CRB II, Suite 1M16, 1550 Orleans Street, Baltimore, MD 21231, USA.
authors: Jaishri
authors: J
authors: Blakeley
authors: Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA, USA ; Neurofibromatosis Clinic, Pappas Center for Neuro-Oncology, Massachusetts General Hospital, 55 Fruit Street, YAW 9, Boston, MA 02114, USA.
authors: Scott
authors: S
authors: Plotkin
authors: Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA ; Pharmacology & Experimental Therapeutics Section, Pediatric Oncology Branch, NCI, CCR, Room 1-5750, 10 Center Drive, 10-CRC, MSC 1101, Bethesda, MD 20892, USA.
authors: Brigitte
authors: B
authors: Widemann
authors: The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors: Michael A
authors: MA
authors: Jacobs